Senior Vice President of Industry Strategy
In bringing the Outcome Health platform to nearly 585M annual patient visits in the country, we’ve enhanced the moment of care experience, and empowered millions of patients, caregivers and physicians to make better health decisions. But innovation isn’t limited to the technology itself – it extends to the ways that we approach data and analytical methods, which allow us for the first time to measure true improvements in the outcomes that matter.
Let’s take a look at how we can help drive and measure adherence. Today, 50% of medications for chronic conditions are not taken as prescribed, and 41% of heart attack patients don’t take their blood pressure medications. Lack of adherence accounts for a staggering $100B-$289B in incremental health care spend according to the Annals of Internal Medicine – an enormous inefficiency that drives up costs for all stakeholders.
Historically, physicians have struggled to find ways to drive patient adherence with critically important therapeutic regimens. Further, it has been nearly impossible to accurately measure the various levers that could help improve adherence.
Recently, a leading life sciences company developed a ground-breaking treatment for combating a serious cardiovascular condition. In clinical trials, this treatment outperformed all other available treatments in keeping patients healthy and out of the hospital. Despite the proven effectiveness of this treatment and rigorous sales efforts, the company could not increase new patient adoption rates and bolster patient adherence to a prescription regimen. Outcome Health took on the client to help bring relevant information and intelligence regarding the treatment and its impact on patients to cardiology offices around the country.
Offices with Outcome Health’s platform experienced an 11% increase in continuing prescriptions compared to a control, as measured by a third party analytics firm, demonstrating a significant uplift in adherence. Further, in this same test set, Outcome Health drove adoption by new patients, with 25% more new patients started on treatment compared to a non-exposed control group.
In order to more accurately attribute impact, in addition to classic test-control conditions, Outcome Health can cross-reference the treatment writing behaviors of healthcare providers by using de-indentified and anonymous claims data of their patient population. This helps explain not only lift, but gives us the opportunity to identify how and why adherence occurs. While the technology helped enable better decision making, the accuracy with which the life sciences company and Outcome Health were able to track improved outcomes is unprecedented.
Looking forward, we have the opportunity to continue to develop our methodologies to deliver and measure the holistic outcomes that our healthcare ecosystem so critically needs, from the population-level impact of improved adoption and adherence on long-term disease outcomes, to increased efficiency and effectiveness in clinical workflow that results in time savings and improved outcomes delivered by healthcare providers.
Roger Sawhney is Senior Vice President of Industry Strategy at Outcome Health, leading efforts to expand health impact with the world’s leading life sciences companies. With 20 years of experience in the biopharmaceutical industry, Roger focuses on developing, coordinating and implementing strategies to help Outcome Health’s brand clients meet their business goals.
Roger was previously a partner in Bain and Company’s global healthcare and private equity practices, where he enabled healthcare companies to drive strategic position and competitive advantage. He also worked at Novartis as senior vice president and global head of corporate strategy, leading the company’s long range planning, business growth and eHealth efforts, as well as emerging market strategy. He serves on the Board of Directors for the New York Institute of Technology (NYIT).